このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Impact of Dexmedetomidine on Sleep Quality

2021年2月7日 更新者:Dong-Xin Wang、Peking University First Hospital

Impact of Dexmedetomidine Supplemented Analgesia on Sleep Quality in Elderly Patients After Major Surgery: A Randomized, Double-blind, and Placebo-controlled Pilot Study

Sleep disturbances frequently occur in elderly patients after major surgery; and their occurrence are associated with worse outcomes including increased incidence of delirium. Previous studies showed that, for elderly patients admitted to the ICU after non-cardiac surgery, low-dose dexmedetomidine infusion improved to some degree the quality of sleep and reduced the incidence of delirium. The investigators hypothesize that, for elderly patients after major non-cardiac surgery, dexmedetomidine supplemented analgesia can also improve the sleep quality. The purpose of this randomized controlled pilot study is to investigate the impact of dexmedetomidine supplemented analgesia on the sleep quality in elderly patients after major non-cardiac surgery.

調査の概要

詳細な説明

Sleep disturbances usually develop in elderly patients after major surgery, which are manifested as prolonged sleep latencies, shortened sleep duration, frequent wake-up, disordered circadian rhythm, abnormally increased stages 1 and 2 non-rapid eye movement (N1 and N2) sleep, and decreased or absent slow wave sleep (SWS) and rapid eye movement (REM) sleep. Occurrence of sleep disturbances is harmful for the recovery of both physiological and mental functions after surgery, and may even lead to the development of postoperative complications. For example, study showed that postoperative sleep disturbances were associated with increase risks of delirium, cardiovascular events and infections, prolonged durations of stay in ICU and hospital, increased medical expenses and high mortality rate. However, methods that may effectively improve the quality of postoperative sleep are still lacking.

Multiple factors are responsible for the development of sleep disturbances after surgery. These include (1) environmental factors, such as noises, lights, medical and nursing activities, etc.; (2) comorbid diseases, such as cardiovascular disease, inflammatory reaction, infections, etc.; (3) stress response and pain stimulation provoked by surgery, especially major surgery; (4) mechanical ventilation. Studies found significantly disordered circadian rhythms, fragmented sleep and absent REM sleep in mechanically ventilated patients; and (5) multiple medications, such as benzodiazepines, opioids, non-steroidal anti-inflammatory drugs, and glucocorticoids,.

Dexmedetomidine is a high selective alpha 2 adrenoceptor agonist which produces hypnosis and sedation by activating the alpha 2 adrenoceptor in the locus coeruleus of the brain; it is well known that the locus coeruleus is the key part to adjust sleep and awakening. The study of Nelson et al. showed that dexmedetomidine induces the expression of c-Fos in the locus coeruleus nucleus and ventral lateral nucleus in rats' brain, which is similar to the expression of c-Fos during non-rapid eye movement sleep. They presumed that dexmedetomidine activates the endogenous sleep-promoting pathway to produce sedative effects, which is totally different from benzodiazepines and opiates on the mechanism.

A recent study of the investigators showed that, in elderly patients who were admitted to the ICU after surgery and did not require mechanical ventilation, low-dose dexmedetomidine infusion (at a rate of 0.1 ug/kg/h, for 15 hours) prolonged the total sleep time, increased the percentage of N2 sleep (and reduced the percentage of N1 sleep), increased the efficiency of sleep and improved the subjective sleep quality. Another study of the investigators showed that low-dose dexmedetomidine infusion in elderly patients who were admitted to the ICU after non-cardiac surgery improved the subjective sleep quality and reduced the daily prevalences of delirium during the first 3 days after surgery. We hypothesize that dexmedetomidine supplemented analgesia can improve the structure and circadian rhythm of sleep, and reduce the incidence of delirium in elderly patients after major non-cardiac surgery.

Simple randomization was performed. Random numbers were generated in a 1:1 ratio with a block size of 4 using the SAS 9.2 software (SAS Institute, USA). Study drugs (either 200 μg/2 ml dexmedetomidine hydrochloride or 2 ml 0.9% saline) were provided as clear aqueous solution in the same type of 3 ml volume ampules (manufactured by Jiangsu Hengrui Medicine Co, Ltd, China) and encoded according to the randomization results before the study by a pharmacist who did not participate in the rest of the study. The results of randomization were sealed in sequentially numbered envelopes until the end of the study.

Dexmedetomidine was not permitted in either group. Anesthesia was induced with midazolam (0.02-0.03 mg/kg), propofol, and sufentanil. Muscle relaxation was achieved using rocuronium, under some special circumstances, using succinylcholine or awake intubation is feasible. Anesthesia was maintained with a propofol infusion and sufentanil or remifentanil, as well as cis-atracurium, rocuronium, with or without the volatile anesthetic sevoflurane or the inhaled gas nitrous oxide. The Bispectral Index were adjusted between 40 and 60. The Bispectral Index is an electroencephalographic measure of hypnotic depth, which ranging from 0 to 100, with values between 40 and 60 considered optimum.

Sequential randomization numbers were assigned to vials by a pharmacist who was otherwise not involved in the trial. All investigators, clinicians, and patients were therefore completely blinded to treatment allocation. But in case of emergency (such as unexpected, rapid deterioration in a participant's clinical status), clinicians could adjust or stop drug administration if deemed clinically necessary. Unmasking was not allowed unless clearly needed for clinical purposes.

Postoperative analgesia was provided with a patient-controlled intravenous analgesia of the trial drug (either dexmedetomidine 200 μg or 0.9% saline) and 80 mg morphine, diluted with 0.9% saline to 160 ml. The patient-controlled pump was programmed to deliver 2-mL boluses with a lockout interval of 8 minutes and a background infusion at 1 mL/h. We adopt this dosing regimen because it has been safely used in our clinical practice and our previous studies. Patient-controlled analgesia was continued for at least 24 h, but not longer than 72 h after surgery. Other analgesics including non-steroidal anti-inflammatory drugs, acetaminophen, and opioids were administered when considered necessary. Open-label dexmedetomidine was not allowed except for treatment of delirium.

Patients were transferred to the post-anesthesia care unit and remained for at least 30 min, monitoring non-invasive blood pressure, electrocardiogram, and pulse oxygen saturation. Then they were sent to a surgical ward. Non-invasive blood pressure and pulse oxygen saturation were monitored intermittently until next morning. Non-invasive blood pressure and heart rate were then monitored once or twice daily until hospital discharge. Those who were unstable were monitored more frequently and transferred to an intensive care unit for clinical purposes. For postoperative patient who accidently came to the intensive care unit, polysomnography monitoring would not be performed.

Polysomnography was performed with a SOMNO watch plus (SOMNO medics GmbH, Germany) from 9:00 PM on the day of surgery until 6:00 AM on the first day after surgery. Two qualified investigators (Z.-F.Z. and X.-Q.M.) were responsible for attaching the electrodes to the patients. The polysomnogram included six-channel electroencephalogram (F3, F4, C3, C4, O1, O2), two-channel electrooculogram (EOG) and one-channel chin electromyogram (EMG). These data were processed according to the American cademy of Sleep Medicine manual (AASM)automatically and stored safely in a research computer disc. A qualified sleep physician who was blinded to the study protocol and did not participate in data collection and patient care scored the sleep architecture epoch by epoch by using the American cademy of Sleep Medicine manual. Total sleep architecture was divided into wakefulness, NREM sleep (stage 1, stage 2, and stage 3), and REM sleep. Total sleep time was defined as the sum of time spent in any sleep stage during the monitoring period. Sleep efficiency was calculated as the ratio between the total sleep time and the total recording time and expressed as percentage. The percentages of each sleep stage were calculated as the durations of each sleep stage divided by the total sleep time. Sleep fragmentation index was calculated as the average number of arousals and awakenings per hour.

Research staffs were blind to randomization, and were not permitted to communicate with either patients or their doctors about any group assignment or treatment. These who responsible for postoperative assessments was not allowed to participate in anesthesia and perioperative care of patients.

Baseline data included demographic characteristics, surgical diagnosis, pre-operative comorbidities, surgical history, smoking and alcohol consumption, and pre-operative medications and laboratory test results and the Charlson Comorbidity Index. Cognitive function was evaluated with the Mini-Mental State Examination (MMSE), score ranges from 0 to 30, with higher score indicating better function. Sleep quality was evaluated with the Pittsburgh Sleep Quality Index, score ranges from 0 to 21, with higher score indicating worse sleep quality. Subjective sleep quality (Refer to the Richards Campbell sleep scale, a 11-point scale where 0 indicates the best possible sleep and 10 indicates the worst possible sleep) and Pain intensity (A 11-point scale where 0 indicates no pain and 10 indicates the worst pain) were also evaluated. Routine intraoperative monitoring included electrocardiogram, non-invasive blood pressure, pulse oxygen saturation, end-tidal carbon dioxide, volatile anesthetic concentration, and urine output. Intra-arterial pressure and central venous pressure were monitored only if necessary. Postoperative data included, study drug and morphine consumption during patient-controlled analgesia, supplemental analgesics and hypnotics within 5 days, and other medications.

All enrolled patients were assessed twice daily, between 8:00-10:00 AM and 6:00-8:00 PM, until the 5th postoperative day or hospital discharge or death, whichever occurred first. Subjective sleep quality was recorded with Numeric Rating Scale (NRS, an 11-point scale where 0=the best sleep and 10=the worst sleep). Sedation level was assessed using the RASS (Richmond Agitation-Sedation Scale), with scores ranging from -5 (unarousable) to +4 (combative) and 0 indicates alert and calm. If RASS score reached -4 or -5, which meant the patients were extremely sedated or unconsciousness. Delirium was not assessed. Delirium was assessed with CAM-ICU (Confusion Assessment Method for the Intensive Care Unit). Delirium was classified into three motoric subtypes: (1) hyperactive (RASS score was consistently positive, +1 to +4); (2) hypoactive (RASS score was consistently neutral or negative, -3 to 0); and, (3) mixed.

Other prespecified outcomes included postoperative pain intensity both at rest and with movement, which was assessed twice daily at the time of delirium with Numeric Rating Scale (NRS, an 11-point scale where 0=no pain and 10=the worst pain) during the first 5 postoperative days; adverse events from the beginning of patient-controlled analgesia until 72 hours after surgery; postoperative complications within 30 days; 30-day mortality; 30 days after surgery. By using Chinese version Telephone Interview for Cognitive Status-modified (TICS-m; scores ranging from 0 to 48, with higher scores indicating better cognitive function), the cognitive function was assessed. Quality-of-life was assessed with the World Health Organization Quality of Life-brief version, (WHOQOL-BREF; a 24-item questionnaire that provides assessments of the quality of life in physical, psychological, and social relationship, and environmental domains. The score of each domain ranges from 0 to 100, with higher score indicating better function).

研究の種類

介入

入学 (実際)

118

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Beijing
      • Beijing、Beijing、中国、100034
        • Peking University First Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

65年~90年 (高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age >= 65 years
  2. Scheduled to undergo elective non-cardiac major surgery (with expected duration >= 2 hours) under general anesthesia
  3. Transferred to general ward with a patient-controlled intravenous analgesia pump after surgery.

Exclusion Criteria:

  1. Refuse to participate
  2. Preoperative history of schizophrenia, epilepsy, parkinsonism or myasthenia gravis
  3. Patients with preoperative sleep disorders (accepted sedatives or hypnotics within 1 month before surgery) or the STOP-BANG Questionnaire score is 3 or higher
  4. Inability to communicate in the preoperative period because of coma, profound dementia or language barrier
  5. Brain injury or neurosurgery
  6. Preoperative left ventricular ejection fraction < 30%, sick sinus syndrome, severe sinus bradycardia (< 50 beats per minute), or second-degree or above atrioventricular block without pacemaker
  7. Severe hepatic dysfunction (Child-Pugh class C); Severe renal dysfunction (requirement of renal replacement therapy before surgery); ASA classification IV or unlikely to survive for more than 24 hours after surgery
  8. Patients recruited in other studies
  9. Other conditions that are considered unsuitable for study participation

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Dexmedetomidine group
Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
他の名前:
  • Dexmedetomidine supplemented morphine analgesia
プラセボコンパレーター:Placebo group
Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
他の名前:
  • Morphine analgesia

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The percentage of stage N2 sleep
時間枠:During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Determined by polysomnographic monitoring
During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)

二次結果の測定

結果測定
メジャーの説明
時間枠
The duration of stage N1 sleep
時間枠:During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Determined by polysomnographic monitoring
During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
The percentage of stage N1 sleep
時間枠:During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Determined by polysomnographic monitoring
During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
The duration of stage N2 sleep
時間枠:During the night after surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Determined by polysomnographic monitoring
During the night after surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
The duration of stage N3 sleep
時間枠:During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Determined by polysomnographic monitoring
During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
The percentage of stage N3 sleep
時間枠:During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Determined by polysomnographic monitoring
During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
The duration of REM sleep
時間枠:During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Determined by polysomnographic monitoring
During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
The percentage of REM sleep
時間枠:During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Determined by polysomnographic monitoring
During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Total sleep time
時間枠:During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Total time spent in any sleep stage during the monitoring period. Determined by polysomnographic monitoring.
During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Sleep efficiency
時間枠:During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
The ratio between the total sleep time and the total recording time and expressed as percentage. Determined by polysomnographic monitoring.
During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
Sleep fragmentation index
時間枠:During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)
The average number of arousals and awakenings per hour of sleep. Determined by polysomnographic monitoring
During the night of surgery (from 9 pm on the day of surgery to 6 am on the first day after surgery)

その他の成果指標

結果測定
メジャーの説明
時間枠
手術後の入院期間
時間枠:手術後30日まで
手術後の入院期間
手術後30日まで
Pain intensity
時間枠:Up to the fifth day after surgery
Estimated with numeric rating scale, where 0 = no pain and 10 the most severe pain
Up to the fifth day after surgery
Subjective sleep quality
時間枠:Up to the fifth day after surgery
Estimated with numeric rating scale, where 0 = the best sleep and 10 the worst sleep.
Up to the fifth day after surgery
Sedation level
時間枠:Up to the fifth day after surgery
Assessed using the Richmond Agitation-Sedation Scale (RASS), with scores ranging from -5 (unarousable) to +4 (combative) and 0 indicates alert and calm.
Up to the fifth day after surgery
Cumulative consumption of morphine
時間枠:Up to the fifth day after surgery
Cumulative morphine consumption after surgery
Up to the fifth day after surgery
Incidence of delirium
時間枠:During the first 5 days after surgery
Incidence of delirium within 5 days after surgery
During the first 5 days after surgery
Incidence of postoperative complications
時間枠:Up 30 days after surgery
Incidence of non-delirium complications within 30 days after surgery
Up 30 days after surgery
30-day mortality
時間枠:On the 30th day after surgery
All cause mortality on the 30th day after surgery
On the 30th day after surgery
Quality of life
時間枠:On the 30th day after surgery
Quality of life is assessed with the World Health Organization Quality of Life-brief version (WHOQOL-BREF; a 24-item questionnaire that provides assessments of the quality of life in 4 domains. The score of each domain ranges from 0 to 100, with higher score indicating better function).
On the 30th day after surgery
Cognitive function
時間枠:On the 30th day after surgery
Cognitive function is assessed with the Telephone Interview for Cognitive Status-modified (TICS-m; score ranges from 0 to 50, with higher score indicating better function).
On the 30th day after surgery

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2017年6月26日

一次修了 (実際)

2020年1月16日

研究の完了 (実際)

2020年2月18日

試験登録日

最初に提出

2017年4月2日

QC基準を満たした最初の提出物

2017年4月17日

最初の投稿 (実際)

2017年4月18日

学習記録の更新

投稿された最後の更新 (実際)

2021年2月10日

QC基準を満たした最後の更新が送信されました

2021年2月7日

最終確認日

2021年2月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

Dexmedetomidineの臨床試験

購読する